Key facts
- CellPhire Therapeutics’s last known valuation is $105.3M (Mar 2021).
- It has raised $51.2M; the latest was Later Stage VC ($5.0M) in Dec 2025.
- Notable investors include United States Department of War, Keiretsu Forum, TEDCO, Simcah Management, Circadian Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CellPhire Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for CellPhire Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellPhire Therapeutics
Operator of a clinical-stage biotechnology company intended to design long shelf-life platelet-derived therapeutics. The company's technology has applications that have potential applications in healthcare fields, from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine, to clinical and research diagnostic reagents, enabling physicians to maintain an adequate supply while treating bleeding casualties.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2005
- Employees
- 48
- Website
- cellphire.com/
- Ownership
- Privately Held (backing)
CellPhire Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellPhire Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellPhire Therapeutics in its N-PORT filings yet. We sweep new filings monthly.